Savulescu Camelia, Prats-Uribe Albert, Brolin Kim, Uusküla Anneli, Bergin Colm, Fleming Catherine, Zvirbulis Viesturs, Zavadska Dace, Szułdrzyński Konstanty, Gaio Vânia, Popescu Corneliu Petru, Craiu Mihai, Cisneros Maria, Latorre-Millán Miriam, Lohur Liis, McGrath Jonathan, Ferguson Lauren, Abolina Ilze, Gravele Dagne, Machado Ausenda, Florescu Simin Aysel, Lazar Mihaela, Subirats Pilar, Clusa Cuesta Laura, Sui Jacklyn, Kenny Claire, Krievins Dainis, Barzdina Elza Anna, Melo Aryse, Kosa Alma Gabriela, Miron Victor Daniel, Muñoz-Almagro Carmen, Milagro Ana María, Bacci Sabrina, Kramarz Piotr, Nardone Anthony
Department of Epidemiology, Epiconcept, Paris, France.
Department of Epidemiology, Epiconcept, Paris, France.
Vaccine. 2025 Jan 25;45:126615. doi: 10.1016/j.vaccine.2024.126615. Epub 2024 Dec 25.
Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared to the first booster, against laboratory-confirmed SARS-CoV-2 infection in HCWs.
In a prospective cohort study among HCWs from 12 European hospitals, we collected nasopharyngeal or saliva samples at enrolment and during weekly/fortnightly follow-up between October 2022 and May 2023. We estimated rVE of the second versus first COVID-19 vaccine booster dose against SARS-CoV-2 infection, overall, by time since second booster and restricted to the bivalent vaccines only. Using Cox regression, we calculated the rVE as (1-hazard ratio)*100, adjusting for hospital, age, sex, prior SARS-CoV-2 infection and at least one underlying condition.
Among the 979 included HCWs eligible for a second booster vaccination, 392 (40 %) received it and 192 (20 %) presented an infection during the study period. The rVE of the second versus first booster dose was -5 % (95 %CI: -46; 25) overall, 3 % (-46; 36) in the 7-89 days after receiving the second booster dose. The rVE was 11 % (-43; 45) when restricted to the use of bivalent vaccines only.
The bivalent COVID-19 could have reduced the risk of SARS-CoV-2 infection among HCWs by 11 %. However, we note the limitation of imprecise rVE estimates due to the proportion of monovalent vaccine used in the study, the small sample size and the study being conducted during the predominant circulation of XBB.1.5 sub-lineage. COVID-19 vaccine effectiveness studies in HCWs can provide important evidence to inform the optimal timing and the use of updated COVID-19 vaccines.
建议医护人员重复接种新冠病毒加强针以维持防护效果。我们评估了新冠病毒疫苗第二剂加强针相对于第一剂加强针，在预防医护人员实验室确诊的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染方面的相对疫苗效力（rVE）。
在一项针对来自12家欧洲医院医护人员的前瞻性队列研究中，我们在2022年10月至2023年5月期间招募时以及每周/每两周随访期间收集鼻咽或唾液样本。我们总体上、按第二剂加强针接种后的时间，并仅针对二价疫苗，评估了新冠病毒疫苗第二剂加强针相对于第一剂加强针预防SARS-CoV-2感染的rVE。使用Cox回归，我们将rVE计算为(1 - 风险比)*100，并对医院、年龄、性别、既往SARS-CoV-2感染和至少一种基础疾病进行了调整。
在979名符合接种第二剂加强针条件的医护人员中，392人（40%）接种了第二剂加强针，192人（20%）在研究期间出现感染。第二剂加强针相对于第一剂加强针的rVE总体为 -5%（95%置信区间：-46；25），在接种第二剂加强针后的7 - 89天为3%（-46；36）。仅使用二价疫苗时，rVE为11%（-43；45）。
二价新冠病毒疫苗可能使医护人员中SARS-CoV-2感染风险降低了11%。然而，我们注意到由于研究中使用的单价疫苗比例、样本量小以及研究在XBB.1.5亚谱系为主的传播期间进行，rVE估计值不精确存在局限性。医护人员中的新冠病毒疫苗效力研究可为确定最佳接种时间和更新型新冠病毒疫苗的使用提供重要证据。
Zotero 插件
